1-Bromo-7-chloroimidazo[1,5-a]pyridine

Catalog No.: 
ACPIYS256
CAS No.: 
1781789-02-3
Molecular Formula: 
C7H4BrClN2
Molecular Weight: 
231.48
1-Bromo-7-chloroimidazo[1,5-a]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%
100mg95%
250mg95%

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Bromo-7-chloroimidazo[1,5-a]pyridine
IUPAC Name1-bromo-7-chloroimidazo[1,5-a]pyridine
MDL No.MFCD33412169
Molecular FormulaC7H4BrClN2
Molecular Weight231.48
SMILESClC1=CC2=C(Br)N=CN2C=C1
InChI KeyGAIJHHDZCNMCOD-UHFFFAOYSA-N
Synonym1-bromo-7-chloroimidazo[1,5-a]pyridine;Imidazo[1,5-a]pyridine, 1-bromo-7-chloro-
CAS No.1781789-02-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACPIYS256 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEDMW612 route compound structure diagram
    ACEDMW6126108-23-2In Stock
  4. Then
  5. ACPIYS256 route product structure diagram
    ACPIYS2561781789-02-3
Inquiry

2. ACPIYS256 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFXPJ467 route compound structure diagram
    ACFXPJ46713963-58-1In Stock
  4. Then
  5. ACPIYS256 route product structure diagram
    ACPIYS2561781789-02-3
Inquiry

3. ACPIYS256 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPIYS256 route product structure diagram
    ACPIYS2561781789-02-3
Inquiry

Comments (0)